SCHEMBL883779

SCHEMBL883779

Cc1ccc2c3ccc4c5ccccc5n(-c5ccccc5)c4c3n(-c3ccccc3)c2c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.55
ATM Q13315 2/20 0.55
L3MBTL1 Q9Y468 2/20 0.55
HTT P42858 3/20 0.39
MAPT P10636 2/20 0.39
LMNA P02545 1/20 0.39
MAPK8 P45983 2/20 0.39
ALKBH5 Q6P6C2 1/20 0.39
FTO Q9C0B1 1/20 0.39
MAT2A P31153 1/20 0.38
PGR P06401 1/20 0.38
MAPK9 P45984 1/20 0.38
MAPK1 P28482 1/20 0.38
FGFR1 P11362 1/20 0.37
KMT2A Q03164 3/20 0.37
MEN1 O00255 2/20 0.37
PLA2G2A P14555 1/20 0.37
ALDH1A1 P00352 1/20 0.37
POLB P06746 1/20 0.37
TSHR P16473 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26451730 0.94 KDM4E (0.53) KDM4EATML3MBTL1HTTMAPT
SCHEMBL883782 0.92 KDM4E (0.53) KDM4EATML3MBTL1HTTMAPT
SCHEMBL883474 0.91 KDM4E (0.67) KDM4EATML3MBTL1HTTMAPT
SCHEMBL15451799 0.90 KDM4E (0.59) KDM4EATML3MBTL1HTTMAPT
SCHEMBL16976993 0.89 L3MBTL1 (0.53) KDM4EATML3MBTL1MAPTLMNA
SCHEMBL10206196 0.88 KDM4E (0.50) KDM4EATML3MBTL1HTTMAPT
SCHEMBL10206157 0.88 KDM4E (0.50) KDM4EATML3MBTL1HTTMAPT
SCHEMBL1104947 0.88 KDM4E (0.62) KDM4EATML3MBTL1HTTMAPT
SCHEMBL17589474 0.88 KDM4E (0.42) KDM4EATML3MBTL1HTTMAPT
SCHEMBL22851963 0.88 ATM (0.46) KDM4EATML3MBTL1HTTMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11917913-B2 Substituted oxepines MERCK PATENT GMBH (DE) 2024-02-27 US disclosed
US-11917913-B2 Substituted oxepines MERCK PATENT GMBH (DE) 2024-02-27 US disclosed
US-20190280218-A1 SUBSTITUTED OXEPINES MERCK PATENT GMBH (DE) 2019-09-12 US disclosed
US-10374170-B2 Substituted oxepines MERCK PATENT GMBH (DE) 2019-08-06 US disclosed
EP-2673249-B1 SUBSTITUTED DIBENZONAPHTHACENE MERCK PATENT GMBH (DE) 2019-04-03 EP disclosed
EP-2651862-B1 SUBSTITUTED TETRAARYLBENZENES MERCK PATENT GMBH (DE) 2017-05-10 EP disclosed
US-9598637-B2 Phosphorus-containing metal complexes MERCK PATENT GMBH (DE) 2017-03-21 US disclosed
US-9598637-B2 Phosphorus-containing metal complexes MERCK PATENT GMBH (DE) 2017-03-21 US disclosed
EP-3121183-A1 METALS CONTAINING ORGANIC COMPLEXES Merck Patent GmbH (DE) 2017-01-25 EP disclosed
EP-2896627-B1 Metals containing organic complexes MERCK PATENT GMBH (DE) 2016-12-21 EP disclosed
US-20150057445-A1 SUBSTITUTED TETRAARYLBENZENES MERCK PATENT GMBH (DE) 2015-02-26 US disclosed
EP-2593184-B1 METAL COMPLEXES WITH ORGANIC LIGANDS AND THE USE THEREOF IN OLEDS MERCK PATENT GMBH (DE) 2014-12-31 EP disclosed
US-20130253617-A1 PHOSPHORUS-CONTAINING METAL COMPLEXES MERCK PATENT GMBH (DE) 2013-09-26 US disclosed
US-20130253617-A1 PHOSPHORUS-CONTAINING METAL COMPLEXES MERCK PATENT GMBH (DE) 2013-09-26 US disclosed
US-20130116755-A1 METAL COMPLEXES WITH ORGANIC LIGANDS AND USE THEREOF IN OLEDS MERCK PATENT GMBH (DE) 2013-05-09 US disclosed
US-20130116755-A1 METAL COMPLEXES WITH ORGANIC LIGANDS AND USE THEREOF IN OLEDS MERCK PATENT GMBH (DE) 2013-05-09 US disclosed
WO-2012107163-A1 SUBSTITUTED DIBENZONAPHTHACENE MERCK PATENT GMBH (DE) 2012-08-16 WO disclosed
WO-2012079678-A1 SUBSTITUTED TETRAARYLBENZENES MERCK PATENT GMBH (DE) 2012-06-21 WO disclosed
WO-2012038029-A1 PHOSPHORUS-CONTAINING METAL COMPLEXES MERCK PATENT GMBH (DE) 2012-03-29 WO disclosed
WO-2012007103-A1 METAL COMPLEXES WITH ORGANIC LIGANDS AND USE THEREOF IN OLEDS MERCK PATENT GMBH (DE) 2012-01-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11917913-B2 Substituted oxepines OXGR1, OXTR, OCIAD2 KDM4E 710/4885ATM 1550/4885L3MBTL1 1480/4885
US-10374170-B2 Substituted oxepines OXGR1, OXTR, OCIAD2 KDM4E 710/4885ATM 1550/4885L3MBTL1 1480/4885
US-20190280218-A1 SUBSTITUTED OXEPINES OXGR1, OXTR, OCIAD2 KDM4E 710/4885ATM 1550/4885L3MBTL1 1480/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.